Laboratory of Hepatitis Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD.
Hepatology. 2014 Mar;59(3):803-13. doi: 10.1002/hep.26747. Epub 2014 Jan 28.
Vaccination of chimpanzees against hepatitis C virus (HCV) using T-cell-based vaccines targeting nonstructural proteins has not resulted in the same levels of control and clearance as those seen in animals reexposed after HCV clearance. We hypothesized that the outcome of infection depends on the different subtypes of activated T cells. We used multicolor flow cytometry to evaluate activation (CD38+/HLA-DR+) and proliferation (Ki67+/Bcl-2-low) profiles of CD4+ and CD8+ T cells in peripheral blood before and after challenge in chimpanzees vaccinated using DNA/adenovirus, mock-vaccinated, and chimpanzees that had spontaneously cleared infection (rechallenged). The frequencies of activated or proliferating CD8+ T cells peaked at 2 weeks postchallenge in the vaccinated and rechallenged animals, coinciding with reductions in viral titers. However, the magnitude of the responses did not correlate with outcome or sustained control of viral replication. In contrast, proliferation of the CD8+ T cells coexpressing HLA-DR either with or without CD38 expression was significantly higher at challenge in animals that rapidly cleared HCV and remained so throughout the follow-up period.
Our data suggest that the appearance of proliferating HLA-DR+/CD8+ T cells can be used as a predictor of a successfully primed memory immune response against HCV and as a marker of effective vaccination in clinical trials.
使用针对非结构蛋白的基于 T 细胞的疫苗对黑猩猩进行丙型肝炎病毒 (HCV) 疫苗接种,并未产生与 HCV 清除后再次暴露的动物相同水平的控制和清除效果。我们假设感染的结果取决于激活 T 细胞的不同亚型。我们使用多色流式细胞术评估了用 DNA/腺病毒接种疫苗、假接种疫苗和自然清除感染(再次挑战)的黑猩猩在挑战前后外周血中 CD4+和 CD8+T 细胞的激活(CD38+/HLA-DR+)和增殖(Ki67+/Bcl-2-低)谱。在接种疫苗和再次挑战的动物中,激活或增殖的 CD8+T 细胞的频率在挑战后 2 周达到峰值,与病毒滴度的降低相一致。然而,反应的幅度与结果或病毒复制的持续控制无关。相比之下,在 HCV 迅速清除且在整个随访期间保持如此的动物中,在挑战时表达 HLA-DR 的 CD8+T 细胞的增殖或同时表达 CD38 和 HLA-DR 的 CD8+T 细胞的增殖明显更高。
我们的数据表明,增殖的 HLA-DR+/CD8+T 细胞的出现可用作针对 HCV 成功引发的记忆免疫反应的预测指标,并且可用作临床试验中有效疫苗接种的标志物。